Literature DB >> 32448613

Alkaloids of fascaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review.

Irina Lyakhova1, Mariia Piatkova1, Valeriia Gulaia2, Aleksandr Romanishin2, Mikhail Shmelev2, Andrey Bryukhovetskiy3, Aruna Sharma4, Hari Shanker Sharma4, Rodion Khotimchenko5, Igor Bryukhovetskiy6.   

Abstract

Glioblastoma is one of the most aggressive human brain tumors. Even following all the modern protocols of complex treatment, the median patient survival typically does not exceed 15 months. This review analyzes the main reasons for glioblastoma resistance to therapy, as well as attempts at categorizing the main approaches to increasing chemotherapy efficiency. Special emphasis is placed on the specific group of compounds, known as marine alkaloids and their synthetic derivatives exerting a general antitumor effect on glioblastoma cells. The unique mechanisms of marine alkaloid influence on the tumor cells prompt considering them as a promising basis for creating new chemotherapeutic agents for glioblastoma treatment.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Fascaplysin; Glioblastoma multiforme; Temozolomide

Mesh:

Substances:

Year:  2020        PMID: 32448613     DOI: 10.1016/bs.irn.2020.03.010

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  1 in total

1.  Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.

Authors:  Adelina Plangger; Barbara Rath; Maximilian Hochmair; Martin Funovics; Christoph Neumayer; Robert Zeillinger; Gerhard Hamilton
Journal:  Invest New Drugs       Date:  2021-10-01       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.